Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

AI Integration in Breast Cancer Trials: MEDSIR and Ataraxis AI Collaborate

Spanish oncology research organization Medica Scientia Innovation Research (MEDSIR) has announced a groundbreaking collaboration with New York-based Ataraxis AI to incorporate artificial intelligence into breast cancer clinical trials. This partnership aims to enhance patient outcome predictions and personalize cancer care, marking a significant step forward in oncology research.

NoahAI News10/7/2025

RSNA Ventures Launches, Partners with Rad AI to Integrate Generative AI in Radiology Workflow

The Radiological Society of North America (RSNA) has made a significant move in the field of radiology by launching RSNA Ventures, a new subsidiary aimed at accelerating innovation in medical imaging. In a strategic partnership, RSNA Ventures has joined forces with Rad AI, a leader in generative AI solutions for radiology, to integrate RSNA's extensive peer-reviewed knowledge directly into radiologists' workflows.

NoahAI News10/7/2025

AstraZeneca Expands AI Capabilities with $555M Algen Alliance

AstraZeneca continues to bolster its artificial intelligence (AI) portfolio, announcing a new partnership with California-based Algen Biotechnologies. The collaboration, which could reach up to $555 million in total value, aims to advance novel therapies in immunology using Algen's proprietary AlgenBrain platform.

NoahAI News10/6/2025

Chiesi and Arbor Biotechnologies Forge $2.1B Alliance for Rare Disease Gene Editing Therapies

Italy's Chiesi Group and California-based Arbor Biotechnologies have announced a landmark collaboration worth up to $2.1 billion, focusing on gene editing therapies for rare diseases. The partnership centers on ABO-101, a promising treatment for primary hyperoxaluria type 1 (PH1), and grants Chiesi access to Arbor's proprietary gene editing technologies.

NoahAI News10/6/2025

Myeloid Therapeutics Rebrands as Create Medicines, Expands Pipeline Beyond Myeloid Cells

Myeloid Therapeutics, a biotech company known for its focus on myeloid cell-based therapies, has announced a significant rebranding and expansion of its pipeline. The company, now known as Create Medicines, is broadening its scope to include multiple immune cell types and advancing several promising candidates in oncology and immunology.

NoahAI News10/6/2025

Skye Bioscience's Obesity Drug Fails to Impress in Phase 2 Study, Casting Shadow on CB1 Inhibitor Class

Skye Bioscience's experimental obesity treatment, nimacimab, has fallen short of expectations in a phase 2 clinical trial, dealing another blow to the troubled CB1 inhibitor class of drugs. The study results, released on October 6, 2025, have sent shockwaves through the pharmaceutical industry and caused Skye's stock to plummet by over 60% in early premarket trading.

NoahAI News10/6/2025

AstraZeneca and Algen Biotechnologies Forge $555M AI Partnership for Immunology Drug Discovery

AstraZeneca, a leading pharmaceutical company, has entered into a significant partnership with San Francisco-based Algen Biotechnologies, leveraging artificial intelligence to accelerate drug discovery in the field of immunology. The collaboration, valued at up to $555 million, aims to harness Algen's AI platform to identify and develop novel immunology targets.

NoahAI News10/6/2025

T Cell Engagers: A Breakthrough in Autoimmune Disease Treatment

In a significant development for the pharmaceutical industry, T cell engagers are emerging as a promising new approach to treating autoimmune diseases. This novel class of biologics aims to reset the immune system, potentially offering long-lasting remission for millions of patients worldwide.

NoahAI News10/6/2025

Patient Recruitment Partners: A Strategic Ally for Clinical Trial Success

In the ever-evolving landscape of clinical trials, a paradigm shift is occurring in how pharmaceutical companies approach patient recruitment. Rather than viewing recruitment specialists as a last resort for struggling studies, industry leaders are recognizing the value of engaging these partners from the outset of trial planning. This proactive approach is proving to be a game-changer in ensuring timely, efficient, and successful clinical studies.

NoahAI News10/6/2025

Cell and Gene Therapy Sector Shows Mixed Signals Amid Ongoing Challenges and Opportunities

The cell and gene therapy (CGT) sector is experiencing a period of flux, with recent developments pointing to both challenges and opportunities. As industry leaders gather for the annual Meeting on the Mesa in Phoenix, Arizona, the landscape of CGT is marked by increased M&A activity and regulatory support, contrasted with persistent commercialization hurdles and investor hesitancy.

NoahAI News10/6/2025

Gene Therapy's Safety and Economics: Shaping the Future of the Industry

Recent developments in the gene therapy sector have highlighted the critical importance of safety and economic viability in determining the success of new treatments. Industry experts are calling for a paradigm shift in approach, emphasizing targeted delivery methods and human-relevant testing models to overcome challenges that have plagued the field.

NoahAI News10/6/2025

Next-Generation MS Treatments: Beyond BTK Inhibitors

Multiple sclerosis (MS) researchers and pharmaceutical companies are pushing the boundaries of treatment options, looking beyond the much-anticipated Bruton's tyrosine kinase (BTK) inhibitors to explore neuroprotective and remyelination strategies. This shift in focus could potentially revolutionize MS treatment, moving from symptom management to disease modification and even reversal.

NoahAI News10/6/2025

«1...35 36 37...67 »